Acceptability of Hepatitis C screening and treatment during pregnancy in pregnant women in Egypt, Pakistan and Ukraine

Authors:

Karen Scott¹, Elizabeth Chappell¹, Aya Mostafa², Alla Volokha³, Nida Najmi⁴, Fatma Ebeid⁵, Svitlana Posokhova⁶, Raheel Sikandar⁷, Marta Vasylyev⁸, Saima Zulfiqar⁹, Viacheslav Kaminskyi^{3, 10}, Sarah Pett^{1,11}, Ruslan Malyuta¹², Ruslana Karpus¹⁰, Yomna Ayman², Rania H M Ahmed¹³, Saeed Hamid¹⁴, Manal H El-Sayed⁵, Diana Gibb¹, Ali Judd¹, Intira Jeannie Collins¹

- 1: Medical Research Council Clinical Trials Unit at University College London (UCL), UK
- 2: Department of Community, Environmental, and Occupational Medicine, Ain Shams University Faculty of Medicine, Egypt
- 3: Shupyk National Healthcare University of Ukraine, Ukraine
- 4: Department of Obstetrics and Gynaecology, Aga Khan University Hospital, Pakistan.
- 5: Faculty of Medicine, Ain Shams University Research Institute-Clinical Research Centre (MASRI-CRC), Egypt.
- 6: Odesa National Medical University, Ukraine
- 7: Liaquat University of Medical and Health Sciences, Pakistan
- 8: Astar Medical Center, Ukraine
- 9: Sheikh Zayed Medical College and Hospital, Pakistan
- 10: Kyiv City Center of Reproductive and Perinatal Medicine, Ukraine
- 11: Institute for Global Health, UCL, UK
- 12: United Nations Children's Fund (UNICEF), Europe and Central Asia Regional Office (ECARO)
- 13: Department of Gynecology and Obstetrics, Faculty of Medicine, Ain Shams University, Egypt
- 14: Department of Medicine, Aga Khan University, Pakistan.

Corresponding author: Karen Scott, MRC CTU at UCL, 90 High Holborn London WC1V 6LJ.
karen.scott@ucl.ac.uk. +44 20 7670 4932

Abbreviations:

HCV	Hepatitis C virus
DAA	Direct acting antivirals
PCR	Polymerase chain reaction
WHO	World Health Organization
RNA	Ribonucleic acid
LMIC	Low and middle-income countries
HIV	Human immunodeficiency virus

Conflict of interests: MHE-S received an educational grant to attend EASL 2019 (Gilead Sciences) and minor honorarium for participating in a podcast on career development and achievements in viral hepatitis (Gilead Sciences).

Funding: This survey was conducted as part of the “HCVAVERT” study, funded by the UK Medical Research Council (ref MR/R019746/1). The MRC CTU at UCL is supported by the Medical Research Council (programme number MC_UU_12023/26).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract:

The risk of vertical transmission of hepatitis C virus (HCV) is $\approx 6\%$, and there is growing evidence that maternal HCV adversely affects pregnancy and infant outcomes. However, antenatal HCV screening is not routinely provided in most settings, and direct acting antivirals (DAA) are not approved for pregnant/breastfeeding women. We conducted a cross-sectional survey of pregnant/post-partum women in Egypt, Pakistan and Ukraine to assess the acceptability of universal antenatal HCV screening and DAA treatment in the scenario of DAAs being approved for use in pregnancy. Among 630 women ($n=210$ per country), 73% were pregnant and 27% postpartum, 27% ever HCV antibody or PCR positive. Overall, 93% of women supported HCV screening and 88% would take DAAs in pregnancy (92%, 98% and 73% in Egypt, Pakistan and Ukraine, respectively), mostly to prevent vertical transmission/adverse pregnancy outcomes. Clinical trials to evaluate the safety and efficacy of DAAs in pregnancy are urgently needed.

Keywords: hepatitis C, pregnancy, DAAs, screening, acceptability

INTRODUCTION

Chronic hepatitis C (HCV) in women of childbearing age is a major global public health concern with an estimated 15 million women aged 15–49 years,¹ living with HCV globally. The risk of HCV vertical transmission is ~6%, with most of the estimated global population of 3 million children² living with HCV thought to have acquired it this way. In addition there is growing evidence of adverse pregnancy and infant outcomes associated with maternal HCV, including intrahepatic cholestasis of pregnancy, preterm birth, and low birth weight.³

In 2016 the World Health Organization (WHO) adopted new goals for global elimination of viral hepatitis by 2030. However, pregnant and breastfeeding women and young children are currently excluded from HCV elimination strategies; few countries recommend routine screening in pregnancy, with many imposing additional charges which limits uptake,⁴ and direct acting antivirals (DAAs) are not licensed for use in pregnancy, breastfeeding or for children aged <3 years. International guidelines currently recommend pregnant women with chronic HCV (i.e. RNA positive) be referred for treatment after cessation of breastfeeding. However, in many low and middle-income countries (LMIC), women commonly breastfeed for ≥2 years, and have multiple pregnancies in rapid succession, limiting opportunities to treat. Studies in both high-income and LMIC have reported poor (<50%) retention in the HCV cascade of care among pregnant women and exposed infants, and low DAA uptake among women post-partum.^{5,6}

Antenatal HCV screening and treatment in pregnancy could cure maternal HCV and prevent vertical transmission and associated adverse pregnancy and infant outcomes, and substantially advance progress towards global elimination targets. A small phase I study in the USA assessed the pharmacokinetics of Harvoni® (sofosbuvir/ ledipasvir) in eight pregnant women from 24 weeks gestation; all women completed the 12-week treatment and had adequate drug exposure, all had viral suppression and functional cure by time of delivery, and no safety signals were identified.⁷ Other small studies have reported off-label use of DAAs in pregnant women in routine care, or conception during DAA treatment, again with no safety signals reported.^{8,9} There is increasing recognition of the need for large clinical trials to assess the safety and efficacy of DAAs to cure pregnant women and prevent vertical transmission,¹⁰ as well as studies on likely uptake of HCV screening and treatment in pregnancy. One study, by Kushner et al, examined the acceptability of HCV screening and treatment in pregnancy in the USA. The study surveyed 121 non-pregnant women with current or previous chronic HCV infection; 60% reported willingness to take DAA treatment in pregnancy to reduce the risk of vertical transmission, and 21% would take treatment during pregnancy for maternal cure, even if it did not reduce vertical transmission.¹¹ There are no comparable data from LMICs.

We conducted a cross-sectional survey to assess the acceptability of free universal antenatal HCV screening and potential uptake of DAAs in the scenario of DAAs being approved for use in pregnancy. The survey was conducted in three high HCV burden countries: Egypt, Pakistan and Ukraine. Egypt and Pakistan have generalised HCV epidemics with estimated prevalence in pregnant women of 9%¹² and 6%¹³ respectively. Ukraine has a concentrated HCV epidemic with high prevalence among people living with HIV.¹⁴

METHODS

Women aged ≥18 years who were pregnant or had delivered in the last 6 months, and attending participating antenatal clinics and maternity hospitals in Egypt (1 public facility), Pakistan (7 facilities, public and private) or Ukraine (3 public facilities, including 1 HIV antenatal clinic) were invited to participate. All women gave written informed consent. Ethical approval was obtained from ethics committees in each participating country.

A survey was developed in REDCap (Research Electronic Data Capture, www.project-redcap.org) and translated into local languages. Participants in Ukraine could self-complete the survey while those in Pakistan and Egypt completed it with assistance of study staff, due to high prevalence of poor literacy.

Minor local adaptations were made, for example HIV status was not collected in Egypt or Pakistan as this was considered highly sensitive and both countries have low HIV prevalence and no routine HIV testing in pregnancy.^{15, 16} The survey ran from July 2020 to July 2021.

The first section of the survey collected data on socio-demographics, pregnancy, and HCV history and knowledge (24 questions about HCV, risk of transmission, availability of treatment and HCV in pregnancy, summarised as a composite). Participants were then given a factsheet about HCV and pregnancy, adapted from Kushner et al.¹¹ (Appendix 1). After they had read this, the second section collected views on the acceptability of free universal HCV screening and use of DAAs in pregnancy, in the scenario that participants had chronic HCV infection and that DAAs were safe and approved for use in pregnancy. The question about taking DAAs in pregnancy had three response options, adapted from Kushner et al.:¹¹ (i) “Yes, to cure me, even if it does not lower the chance of my baby getting hepatitis C,”; (ii) “Yes, but only if it lowers the chance of my baby getting hepatitis C or has other potential benefits for my baby”; or (iii) “No, I would wait until after my pregnancy to start treatment.”

The target sample size was 630 women (210 per country), of which 50% in Ukraine would be HCV positive (self-reported ever PCR or antibody positive), and up to 20% in Egypt and Pakistan. Ukraine had a higher target as HCV screening is provided routinely to women living with HIV.

Descriptive statistics were used to summarise the characteristics of participants and survey response, overall and by country. Acceptability of treatment in pregnancy (yes for any reason vs. no) was described by key demographic and clinical characteristics: age, highest level of education, household overcrowding score (number of rooms excluding kitchen and bathroom/number of people in home), relationship status, employment status, pregnancy status (currently pregnant vs. given birth in the last 6 months), self-reported HCV status (ever HCV antibody or RNA positive, HCV negative and never tested) and HIV status (Ukraine only), number of previous children, and the composite HCV knowledge score.

RESULTS

Sociodemographic characteristics of the 630 participants are shown in Table 1. Median age was slightly higher in Ukraine, at 33 [interquartile range 28,36] years, and lowest in Pakistan at 29 [26,33] years. Fifty-nine per cent of women in Ukraine self-reported as ever HCV positive compared to 3% and 20% in Egypt and Pakistan, respectively. A quarter of women in Egypt never had an HCV test compared to 10% in Pakistan and 7% in Ukraine. Forty percent of women in Ukraine were living with HIV, of whom 33% were ever HCV positive.

The majority of women in Ukraine (93%) were pregnant at the time of survey compared to two-thirds in Egypt and Pakistan. Most women were married or co-habiting. In Egypt and Pakistan ~40% of women had not completed secondary school education, compared to 9% in Ukraine. The household overcrowding score was highest in Pakistan, signifying more overcrowding. The median HCV knowledge score was 12 [9,15] (of a possible maximum 24) and was comparable across countries, however 13% of women in Egypt reported not having heard of HCV before, compared to ≤3% in Pakistan and Ukraine.

Overall, 93% of women agreed with free universal HCV screening during pregnancy and this was consistent across countries (range 88%-95%) (Supplementary Figure 1). The acceptability of DAAs in pregnancy by country, HCV status, and HIV status (Ukraine only) is shown in Figure 1. Overall 88% of women reported that they would take DAAs in pregnancy; acceptability was highest in Pakistan (98%) followed by Egypt (91%) and Ukraine (73%). The majority of women would take DAAs in pregnancy to prevent vertical transmission and other potential benefits to the baby (48-90% by country), while a smaller proportion (8-29%) would take DAAs for maternal cure. When results were combined across all countries and stratified by HCV status, acceptability was highest among HCV negative women (92%) and was lowest among women who ever tested HCV positive at 78%. Among women in Ukraine, acceptability was similar among women

with and without HIV infection.

There was no difference in acceptability of DAAs by the woman's or her partner's employment status, or her HCV knowledge score, in any country (all $p > 0.05$) (Supplementary Table 1). In Egypt, only higher household overcrowding was associated with increased acceptability ($p = 0.018$). In Pakistan, older maternal age ($p = 0.007$), fewer previous children ($p = 0.032$), and higher household overcrowding ($p = 0.047$) were associated with increased acceptability. In Ukraine, being pregnant ($p = 0.047$) and higher education level ($p = 0.031$) were associated with increased acceptability.

DISCUSSION

To our knowledge, this is the largest study to date on acceptability of HCV screening and treatment in pregnant/post-partum women and first in LMICs with high HCV burden. Acceptability of universal antenatal HCV screening was very high at 93%. In the scenario that DAAs were approved for use in pregnancy, acceptability ranged from 78% in Ukraine to 98% in Pakistan. These estimates are substantially higher than the 60% acceptability of DAAs in pregnancy reported among non-pregnant women with current or past history of chronic HCV infection in the USA.¹¹ The difference may be due to our study including women who were currently pregnant or recently delivered and women with known and unknown HCV status, . It may also reflect the broader differences in DAA acceptability during pregnancy across different settings.

In our study, the majority of women would take DAAs in pregnancy to prevent vertical transmission and adverse pregnancy and infant outcomes while fewer reported maternal cure as the main reason to receive treatment. This trend was consistent across the three countries, by HCV and HIV status. We found few individual level factors associated with the acceptability of DAAs, which was in part due the high acceptability observed.

Interestingly, despite a national HCV test and treat campaign in Egypt, with over 50 million screened and 4 million treated since 2015,¹⁷ a small proportion of women (13%) were not aware of HCV, and 25% were never tested. We gave all participants a factsheet to encourage informed responses, however we did not assess whether this information was fully understood or the degree to which it contributed to women's responses.

One of the strengths of our study is the inclusion of women from three countries in different geographic regions with different HCV epidemics, and including public and private clinics and an HIV clinic. A key limitation is that assessment of acceptability was based on a scenario that the woman had chronic HCV, and that DAAs were safe and approved for use in pregnancy, yet the majority of women included in the study in Pakistan and Egypt were HCV negative or had never been tested. However almost 60% of the women in Ukraine were HCV positive, and for this group acceptability was high at 88%. Nonetheless, actual uptake of DAA treatments if approved may differ. Another weakness of the study is that the method of data collection differed across settings whereby most women in Ukraine self-completed the survey on a tablet and all women in Egypt and Pakistan were surveyed by a member of staff. This may have influenced women's responses.

In summary our study found very high acceptability of universal HCV antenatal screening and the use of DAAs in pregnancy, if found to be safe and approved for use in pregnancy. Currently pregnant women with chronic HCV have to wait until they finish breastfeeding before they can seek curative treatment, resulting in long delays in access to treatment and increased risk of disease progression, which may affect maternal and infant outcomes for current and future pregnancies. Studies in the USA¹⁸ and France¹⁹ have reported the cost-effectiveness of universal HCV screening in pregnancy even without the option of treatment during pregnancy, driven by the benefits of identifying women to refer for treatment after breastfeeding and HCV exposed infants to screen. There are no comparable cost-effectiveness analyses in LMIC but preliminary modelling of universal screening and treatment in Ukraine and Egypt suggests substantial potential benefits.²⁰ A DAA pregnancy registry, the Treatment In Pregnancy for Hepatitis C: TIP-HepC Registry, has

been established by the Coalition for Global Hepatitis Elimination at the Taskforce for Global Health to aid reporting of first trimester exposure to DAAs, which will contribute important safety data. Additionally randomised controlled trials on the safety and efficacy of DAAs started later in pregnancy and the breastfeeding period are needed to inform future clinical care and policy to ensure that pregnant women with HCV and their children do not continue to be left behind in the global HCV elimination effort.

References:

1. Dugan E, Blach S, Biondi M, Cai Z, DePaola M, Estes C, et al. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. *Lancet Gastroenterol Hepatol*. 2021;**6**(3)169-84.
2. Schmelzer J, Dugan E, Blach S, Coleman S, Cai Z, DePaola M, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. *Lancet Gastroenterol Hepatol*. 2020;**5**(4)374-92.
3. Benhammou V, Tubiana R, Matheron S, Sellier P, Mandelbrot L, Chenadec JL, et al. HBV or HCV Coinfection in HIV-1-Infected Pregnant Women in France: Prevalence and Pregnancy Outcomes. *J Acquir Immune Defic Syndr*. 2018;**77**(5)439-50.
4. Malik F, Bailey H, Chan P, Collins IJ, Mozalevskis A, Thorne C, et al. Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines. *JHEP Rep*. 2021;**3**(2)100227.
5. Bhardwaj AM, Mhanna MJ, Abughali NF. Maternal risk factors associated with inadequate testing and loss to follow-up in infants with perinatal hepatitis C virus exposure. *J Neonatal Perinatal Med*. 2020;**10**.3233/NPM-190264.
6. Kuncio DE, Newbern EC, Johnson CC, Viner KM. Failure to test and identify perinatally infected children born to Hepatitis C virus-infected women. *Clin Infect Dis*. 2016;**62**(8)980-5.
7. Chappell CA, Scarsi KK, Kirby BJ, Suri V, Gaggar A, Bogen DL, et al. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. *Lancet Microbe*. 2020;**1**(5)e200-e8.
8. AbdAllah M, Alboraie M, Abdel-Razek W, Hassany M, Ammar I, Kamal E, et al. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort. *Liver Int*. 2021;**41**(7)1494-7.
9. Yattoo GN. Treatment of chronic hepatitis C with ledipasvir/sofosbuvir combination during pregnancy. Abstract number O-HCV-38. 27th Annual Conference of Asian Pacific Association for the Study of the Liver; New Delhi, India2018.
10. Judd A, Collins IJ, Pett S, Gibb DM. Labour pains: eliminating HCV in women and children. *Lancet Gastroenterol Hepatol*. 2021;**6**(3)150-1.
11. Kushner T, Cohen J, Tien PC, Terrault NA. Evaluating Women's Preferences for Hepatitis C Treatment During Pregnancy. *Hepatol Commun*. 2018;**2**(11)1306-10.
12. Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. *Sci Rep*. 2018;**8**(1)1661-.
13. Al Kanaani Z, Mahmud S, Kouyoumjian SP, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. *R Soc Open Sci*. 2018;**5**(4)180257.
14. Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. *Epidemiol Infect*. 2014;**142**(2)270-86.
15. UNAIDS. Global AIDS Monitoring 2020 Country progress report - Egypt Geneva; 2020.
16. UNAIDS. Global AIDS Monitoring 2020 Country progress report - Pakistan. Geneva; 2020.
17. Hassanin A, Kamel S, Waked I, Fort M. Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study. *Glob Health Sci Pract*. 2021;**9**(1)187-200.
18. Chaillon A, Rand EB, Reau N, Martin NK. Cost-effectiveness of universal hepatitis C virus screening of pregnant women in the United States. *Clin Infect Dis*. 2019;**69**(11)1888-95.
19. Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pilonel J, Le Strat Y, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. *J Hepatol*. 2018;**69**(4)785-92.
20. Maalej NH, Collins IJ, Ades A, Scott K, Judd A, Chappell E, et al., editors. Modelling the potential effectiveness of different screening and treatment strategies for hepatitis c during pregnancy in Ukraine. International Liver Congress; 2021; Online.

Tables and Figures

Table 1 Sociodemographic characteristics of women participating in the survey by country

		Egypt (n=210)	Pakistan (n=210)	Ukraine (n=210)	Total (n=630)
n (%) or median [IQR]					
Age (years)		30 [26,34]	29 [26,33]	33 [28,36]	30 [26,35]
Age group (years)	18-24	42 (20)	29 (14)	27 (13)	98 (16)
	25-34	117 (56)	150 (71)	105 (50)	372 (59)
	≥35	51 (24)	31 (15)	78 (38)	160 (25)
HCV status (self-report)	Ever HCV positive (antibody or RNA)	7 (3)	42 (20)	123 (59)	172 (27)
	HCV negative	150 (71)	147 (70)	72 (34)	369 (59)
	Never tested	53 (25)	21 (10)	15 (7)	89 (14)
HIV status (self-report)	HIV positive	-	-	83 (40)	83 (13)
	HIV negative	-	-	126 (60)	126 (20)
Pregnancy status	Gave birth in last 6 months	75 (36)	78 (37)	14 (7)	167 (27)
	Currently pregnant	135 (64)	132 (63)	196 (93)	463 (73)
Parity	First pregnancy	35 (17)	40 (19)	81 (39)	156 (25)
	Previous pregnancy	175 (83)	170 (81)	129 (61)	474 (75)
Number of previous children (not including recent/current pregnancy)		2 [1,3]	2 [1,3]	1 [1,2]	2 [1,3]
Relationship status	Divorced, separated, widowed, single	0 (0)	0 (0)	23 (11)	23 (4)
	Married, co-habiting	210 (100)	210 (100)	186 (89)	606 (96)
Highest level of education	Less than secondary	89 (42)	85 (40)	19 (9)	193 (31)
	Completed secondary school/college	81 (39)	39 (19)	110 (52)	230 (37)

	University or higher	40 (19)	86 (41)	81 (39)	207 (33)
Overcrowding score †		1.5 [1.0,2.0]	1.8 [1.3,2.7]	1.0 [1.0,1.7]	1.5 [1.0,2.0]
Employment status	Full-time or student	22 (10)	35 (17)	71 (34)	128 (20)
	Part-time	13 (6)	22 (10)	39 (19)	74 (12)
	Unemployed/other	175 (83)	153 (73)	100 (47)	428 (68)
Partner's employment status	Full-time or student	98 (47)	159 (76)	145 (69)	402 (64)
	Part-time	95 (45)	40 (19)	38 (18)	173 (27)
	Unemployed/other	17 (8)	11 (5)	4 (2)	32 (5)
	N/A (no partner)	0 (0)	0 (0)	23 (11)	23 (4)
Ever heard of HCV	No	27 (13)	5 (2)	7 (3)	39 (6)
	Yes	183 (87)	205 (98)	202 (97)	590 (94)
HCV Knowledge Score ‡		11 [8,14]	11 [9,14]	14 [13,17]	12 [9,15]

†Overcrowding score is number of people in home/ number of rooms (excluding kitchen and bathroom)

‡ HCV knowledge score was derived from allocating a point for each HCV knowledge question correctly answered, max score 24

Note: for all variables p value for comparison between countries <0.01

Figure 1 Acceptability of DAA treatment if known to be safe during pregnancy, by country, self-reported HCV status and self-reported HIV status (among women in Ukraine)

Supplementary Figures and Tables

Supp. Figure 1: Acceptability of universal HCV screening in pregnancy

Supp Table 1: Acceptability of DAAs in pregnancy by key characteristics, by country and overall

Variable		Egypt n=210			Pakistan n=210			Ukraine n=210			All countries n=630		
		Yes, would take DAAs in pregnancy	No, would wait	P*	Yes, would take DAAs in pregnancy	No, would wait	P*	Yes, would take DAAs in pregnancy	No, would wait	P*	Yes, would take DAAs in pregnancy	No, would wait	P*
		n (%) or median [IQR]			n (%) or median [IQR]			n (%) or median [IQR]			n (%) or median [IQR]		
Age (years)	18-24	36 (86)	6 (14)	0.327	26 (90)	3 (10)	0.007	22 (81)	5 (19)	0.558	84 (86)	14 (14)	0.112
	25-34	109 (93)	8 (7)		149 (99)	1 (1)		75 (71)	30 (29)		333 (90)	39 (10)	
	≥35	47 (92)	4 (8)		30 (97)	1 (3)		56 (72)	22 (28)		133 (83)	27 (17)	
HCV status	Ever HCV positive (antibody or RNA)	6 (86)	1 (14)	0.578	40 (95)	2 (5)	0.447	89 (72)	35 (28)	0.592	135 (78)	38 (22)	<0.001
	Never HCV positive	136 (93)	11 (7)		144 (98)	3 (2)		55 (76)	17 (24)		338 (92)	31 (8)	
	Never tested	47 (89)	6 (11)		21 (100)	0 (0)		9 (64)	5 (36)		77 (87)	11 (13)	
HIV status	HIV negative	-	-	-	-	-	-	92 (72)	35 (28)	0.867	-	-	-
	HIV positive	-	-		-	-		61 (73)	22 (27)		-	-	
Pregnancy status	Delivered	70 (93)	5 (7)	0.462	77 (99)	1 (1)	0.422	7 (50)	7 (50)	0.047	154 (92)	13 (8)	0.026
	Currently pregnant	122 (90)	13 (10)		128 (97)	4 (3)		146 (74)	50 (26)		396 (86)	67 (14)	
No. of previous children		2 [1,3]	1 [0,2]	0.424	1 [0,3]	2 [0,4]	0.032	0 [0,1]	1 [0,2]	0.138	1 [0,2]	1 [0,2]	0.138
Education level	Did not complete secondary school	85 (96)	4 (4)	0.188	81 (95)	4 (5)	0.130	9 (47)	10 (53)	0.031	175 (91)	18 (9)	0.073
	Completed secondary school/college	72 (89)	9 (11)		38 (97)	1 (3)		82 (75)	28 (25)		192 (83)	38 (17)	

	Completed university qualification or higher	35 (88)	5 (13)		86 (100)	0 (0)		62 (77)	19 (23)		183 (88)	24 (12)	
Overcrowding score †		1.5 [1.0,2.0]	1.3 [1.0,2.0]	0.018	1.8 [0.3,2.7]	1.6 [1.5,3.7]	0.047	1.0 [1.0,1.7]	1.3 [1.0,2.0]	0.655	1.5 [1.0,2.0]	1.3 [1.0,2.0]	0.655
Employment status	Full-time or student	21 (95)	1 (5)	0.763	33 (94)	2 (6)	0.237	57 (80)	14 (20)	0.224	111 (87)	17 (13)	0.199
	Part-time	12 (92)	1 (8)		21 (95)	1 (5)		27 (69)	12 (31)		60 (81)	14 (19)	
	Unemployed/other	152 (91)	16 (9)		151 (99)	2 (1)		69 (69)	31 (31)		379 (89)	49 (11)	
Partner's employment status	Full-time or student	89 (91)	9 (9)	0.801	156 (98)	3 (2)	0.446	106 (73)	39 (27)	0.985	351 (87)	51 (13)	0.063
	Part-time	88 (93)	7 (7)		38 (95)	2 (5)		28 (74)	10 (26)		154 (89)	19 (11)	
	Unemployed/other	15 (88)	2 (12)		11 (100)	0 (0)		3 (75)	1 (25)		29 (91)	3 (9)	
	No partner	0 (0)	0 (0)		0 (0)	0 (0)		16 (70)	7 (30)		16 (70)	7 (30)	
HCV Knowledge Score		11 [8,14]	12 [8,14]	0.915	11 [9,14]	9 [9,10]	0.845	15 [13,17]	14 [11,16]	0.076	12 [9,15]	13 [11,16]	0.076

† Overcrowding score is number of people in home/ number of rooms (excluding kitchen and bathroom)

* p values from chi squared or t tests

Appendix 1: HCVAVERT Screening and DAA Acceptability Survey for Ukraine

HCVAVERT Screening and DAA Acceptability Survey for Ukraine

PART A – FOR INTERVIEWER COMPLETION

Please ensure that the participant has read the information sheet and signed the consent form, and thus is ready to participate in this survey.

Please complete the following screening questions before starting this survey.

S1	Is the participant pregnant or have they delivered in the last 6 months?	1. No 2. Yes
S2	Is the participant aged ≥ 18 years?	1. No 2. Yes
S3	Is the participant attending an antenatal clinic at any point during her pregnancy or has she been admitted to hospital for delivery or for other medical reasons during pregnancy or is she attending clinic and has given birth in the last 6 months?	1. No 2. Yes
S4	Is the participant willing to provide informed consent to participate?	1. No 2. Yes

If the answer to any of the above questions is “no”, the woman must not participate in this study

S5	Where is the interview taking place?	1. Kiev AIDS Centre 2. Kiev Maternity Hospital 3. Odesa Maternity Hospital 4. Other
S6	QS5 (4) → Please specify	{text}
S7	Is/has the participant?	1. Attending an antenatal clinic at any point during her pregnancy 2. Been admitted to hospital for delivery or for other medical reasons during pregnancy 3. Given birth in the last 6 months
S8	Did the participant need any help completing this survey? (i.e. did you read the questions to them?)	1. No 2. Yes

PART B – FOR THE PARTICIPANT

Thank you for agreeing to participate in our survey about hepatitis C testing and treatment of pregnant women. We will ask you questions about:

- *Your knowledge and understanding of hepatitis C*
- *Your views about testing for hepatitis C during pregnancy*
- *Your views about giving pregnant women treatment to cure hepatitis C*
- *Your knowledge about mother to child transmission of hepatitis C*

We will not collect anything that will identify you, so we will not ask you for your name, address or date of birth. All your responses to the survey questions will be confidential and access will be restricted to the survey researchers only, and not doctors or nurses at this clinic.

Section 1: Sociodemographics

1	How old are you?	{number} years
2	What is your current relationship status?	1. Married or cohabiting 2. Divorced or separated 3. Widowed 4. Single and never married 5. Other
3	Q2 (5) → Please specify	{text}
4	What is your country of birth?	1. Ukraine 2. Other
5	Q4 (2) → Please specify	{text}
6	What is the highest level of education you have completed?	1. No education 2. Less than secondary school 3. Completed secondary school 4. Completed vocational secondary school or college 5. Bachelor's degree/Master's degree/Professional degree (e.g. MD) or Doctoral degree (e.g. PhD)
7	How many rooms does your home have (excluding kitchen and bathrooms)?	{number}
8	How many people (adults and children) usually live at your home?	{number}
9	What is/was your occupational status?	1. Full-time employment 2. Part-time employment 3. Unemployed

		4. Student 5. Other
10	Q9 (5) → Please specify	{text}
11	What is/was your husband or partner's occupational status?	1. Full-time employment 2. Part-time employment 3. Unemployed 4. Student 5. Other
12	Q11 (5) → Please specify	{text}

Section 2: Pregnancy questions		
13	Are you currently pregnant?	1. No 2. Yes
14	Q13 (1) → Did you have your baby in the last 6 months?	1. No 2. Yes
15	Q13 (2) → How many weeks pregnant are you now?	{number} weeks
16	Q14 (2) → How many weeks is it since you gave birth?	{number} weeks
17	Q13 (2) → Do you know if you will have a natural delivery or caesarean section?	1. Natural delivery 2. Planned caesarean section 3. Not sure (e.g. early stages of pregnancy, or baby breech but may turn)
18	Q13 (2) → How do you plan to feed the baby?	1. Exclusive breastfeeding 2. Formula feeding 3. Mixed feeding (breastfeeding and formula) 4. Not sure
19	Q14 (2) → Did you have a natural delivery or planned or emergency caesarean section?	1. Natural delivery 2. Planned caesarean section 3. Emergency caesarean section
20	Q14 (2) → How are you feeding the baby now?	1. Exclusive breastfeeding 2. Formula feeding 3. Mixed feeding (breastfeeding and formula)
21	Q14 (2) → Have you ever breastfed the baby that you are feeding now?	1. No 2. Yes

22	Q14 (1) → Is this your first pregnancy or have you been pregnant in the past?	1. First pregnancy 2. Have been pregnant previously
23	Q14 (2) → Was this your first pregnancy or have you been pregnant in the past?	1. First pregnancy 2. Have been pregnant previously

Section 3: Knowledge about hepatitis C		
24	Have you heard of an illness called hepatitis C?	1. No 2. Yes
25	How is Hepatitis C transmitted? (please tick all that apply)	1. Blood to blood contact 2. Sexual contact 3. Getting a tattoo or body piercing in an unregulated setting 4. Sharing needles and syringes 5. From hepatitis positive mother to child during pregnancy /delivery 6. Breastfeeding 7. Coughing and sneezing 8. Sharing eating utensils 9. Sharing razors or toothbrushes 10. Don't know
26	Can Hepatitis C lead to any of the following illnesses (please tick all that apply)	1. Liver damage / liver failure 2. Cirrhosis (scarring of the liver) 3. Diabetes 4. Liver cancer 5. Stroke 6. Death 7. Don't know
27	Is it possible to treat hepatitis C?	1. Yes, you can cure it 2. Yes, you can treat it but not cure it 3. No, there are no treatments 4. Don't know
28	Can pregnant women take medicine to treat hepatitis C during their pregnancy?	1. No 2. Yes 3. Don't know
29	Are pregnant women who have hepatitis C at increased risk of any of the following? (tick all that apply)	1. Having complications during pregnancy (e.g. gestational diabetes) 2. Having an infant with a low birth weight 3. Having a premature baby 4. Giving hepatitis C to their baby 5. Other 6. None of the above 7. Don't know
30	Q29 (5) → Please specify	{text}

31	Imagine that 100 pregnant woman have the hepatitis C virus. How many of their 100 babies are likely to have the infection?	<ol style="list-style-type: none"> 1. None 2. 2 or less 3. Around 3 to 10 4. Around 10 to 20 5. Around 20 to 30 6. Around 30 to 50 7. More than 50
32	Is it possible to treat children aged under 16 years who have hepatitis C?	<ol style="list-style-type: none"> 1. No 2. Yes, teenagers age 12 and over 3. Yes, children age 3 and over, but not for young children under 3 years of age 4. Don't know

Section 4: Hepatitis C exposure and hepatitis C and HIV testing		
33	Have you ever had any of the following in the past? (tick all that apply)	<ol style="list-style-type: none"> 1. Blood transfusion 2. Tattoos 3. Piercings 4. Direct contact with hepatitis C positive blood through a healthcare job (e.g. needlestick injury) 5. Medical injections or hospital procedures or surgery (including abortion, endoscopy, dialysis) 6. Injections for non-medical purposes (e.g. recreational drug use or traditional healer) 7. A close family member having hepatitis C 8. None of the above 9. Not sure 10. Other
34	Q30 (10) → Please specify	{text}
35	Has your biological mother ever tested positive for hepatitis C?	<ol style="list-style-type: none"> 1. No 2. Yes 3. Don't know
36	Has a sexual partner or family member of yours ever tested positive for hepatitis C?	<ol style="list-style-type: none"> 1. No 2. Yes 3. Don't know
37	Have <u>you</u> ever had a test for hepatitis C?	<ol style="list-style-type: none"> 1. No 2. Yes 3. Don't know
38	Q37 (2) → When was the last time you were tested?	<ol style="list-style-type: none"> 1. During this pregnancy 2. During a previous pregnancy 3. Another time when I was not pregnant
39	Q37 (2) → What was the result?	<ol style="list-style-type: none"> 1. Negative 2. Positive 3. Don't know

40	Q39 (2) → Do you know if the test result was? (tick all that apply)	<ol style="list-style-type: none"> 1. Positive for hepatitis C antibody 2. Positive for hepatitis C virus (i.e. RNA/PCR positive) 3. Positive for hepatitis C but not sure if I was tested for antibody or virus (RNA/PCR)
41	Q37 (2) → Approximately how much did the hepatitis C test cost?	<ol style="list-style-type: none"> 1. Nothing, it was free 2. 100 – 200 UAH 3. 200 – 300 UAH 4. 300 – 500 UAH 5. Don't know 6. Other
42	Q37 (6) → Please specify	{text}
43	Q40 (1-3) → Have you been treated for hepatitis C?	<ol style="list-style-type: none"> 1. No 2. Yes 3. Don't know
42	Q41 (2) → How did you take the medicine to treat your hepatitis C?	<ol style="list-style-type: none"> 1. Weekly injections plus tablet 2. Daily tablets only
43	Q41 (2) → Were you cured?	<ol style="list-style-type: none"> 1. No 2. Yes 3. Don't know
44	Q22 (2) & 23 (2) → How many children do you have who are alive today (not including your current/ recent pregnancy)?	{number}
45	Q44 >0 → Have any of your children been tested for hepatitis C?	<ol style="list-style-type: none"> 1. None have been tested 2. Yes, at least one has 3. Don't know
46	Q45 (2) → Did any of your children test positive for hepatitis C?	<ol style="list-style-type: none"> 1. No 2. Yes 3. Don't know
47	Q46 (2) → How many tested positive for hepatitis C?	{number}
48	Do you have HIV?	<ol style="list-style-type: none"> 1. No 2. Yes 3. Not sure
49	Q13 (2) and Q48 (2) → Are you currently taking antiretroviral drugs for your HIV (i.e. during your pregnancy)?	<ol style="list-style-type: none"> 1. No 2. Yes

50	Q13 (1) and Q48 (2) → Are you currently taking antiretroviral drugs for your HIV (i.e. following delivery of your baby)?	1. No 2. Yes
51	Q48 (2) → Did you take antiretroviral drugs for your HIV during your recent pregnancy?	1. No 2. Yes

Section 5: Acceptability of hepatitis C testing and treatment in pregnancy

A baby can get hepatitis C from its mother during pregnancy, if the mother has tested positive for the hepatitis C virus (RNA/ PCR positive). New hepatitis C medicines are not approved to treat hepatitis C in infants and young children. If a child has hepatitis C at birth they need to wait until they are at least 12 years old to be treated.

The following pictures help show the chances of a baby getting hepatitis C from its mother if the mother has the hepatitis C virus.

6% (6 out of 100) of all babies born to mothers with hepatitis C virus will get hepatitis C from their mother during pregnancy.

11% (11 out of 100) of all babies born to mothers with hepatitis C virus and HIV, and who are not taking HIV medication, will get hepatitis C from their mother during pregnancy.

Less than 11%, and perhaps nearer 6%, of all babies born to mothers with hepatitis C virus and HIV, and who are taking HIV medication and have suppressed HIV, will get hepatitis C from their mother during pregnancy.

Babies born to mothers with hepatitis C virus are at higher risk of having a lower birth weight and being premature than babies born to mothers who are hepatitis C negative.

It is thought that breastfeeding is not a risk for transmitting hepatitis C from a mother to their child.

Studies in animals of hepatitis C medicines suggest that some of these medicines are safe in pregnancy. But because these medicines are new, we do not know for sure if these medicines can hurt a baby during pregnancy in humans.

Testing for hepatitis C is very simple. An initial test tells us whether a pregnant woman has ever come into contact with hepatitis C before, and this is called the “antibody test”. You can sometimes get the results of this test on the same day that you were tested. If this is positive, a second test tells us whether the woman actually has the hepatitis C virus. Results for the second test might take a week or so to come back. If the second test is positive, it means that the woman has active virus in her body, and she can potentially transmit the virus to her infant during pregnancy

Section 6: Questions about your possible exposure to Hepatitis C and HIV testing

52	At the moment pregnant women in Ukraine have to pay for the test for hepatitis C. Do you think all women should be offered free hepatitis C testing in pregnancy?	<ol style="list-style-type: none"> 1. No 2. Yes 3. Don't know
53	Q52 (1) → Why not?	{text}
54	<p>It is not clear whether medicines for curing hepatitis C are safe when taken during pregnancy.</p> <p>Given this, would you consider taking medicine for hepatitis C during pregnancy?</p>	<ol style="list-style-type: none"> 1. Yes, to cure me, even if it does not lower the chance of my baby getting hepatitis C 2. Yes, but only if it lowers the chance of my baby getting hepatitis C or has other benefits for my baby 3. No, I would wait until after my pregnancy to start treatment

	(Please only give one response, whichever you consider your main response)	4. No, I would wait until there were more studies testing these medicines before I decided to start treatment during pregnancy
55	<p>Now, let's pretend that medicines for hepatitis C have been found to be safe for both mother and baby when taken during pregnancy.</p> <p>Given this, and imagining you are hep C positive, would you consider taking medicine for hepatitis C during pregnancy? (Please only give one response, whichever you consider your main response)</p>	<p>1. Yes, to cure me, even if it does not lower the chance of my baby getting hepatitis C</p> <p>2. Yes, but only if it lowers the chance of my baby getting hepatitis C or has other potential benefits for my baby</p> <p>3. No, I would wait until after my pregnancy to start treatment</p>

Thank you for completing this survey.
Please let us know if you have any comments or questions